News

Demonstrating Excellence in Outcomes and Culture

LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations

News

Stay up to date with the latest innovations, company updates, and industry insights as we work to advance health and wellness for all.